Advertisements



Provention Bio expects results of inflammatory bowel disease trials in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Provention Bio sees results of inflammatory bowel disease trials in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

UPMC Health Plan announces $6.3M research contract

UPMC Health Plan announced that the UPMC Center for High-Value Health Care was recently awarded a $6.3 million contract from the Patient-Centered Outcomes Research Institute (PCORI) to improve outcomes for patients with inflammatory bowel disease (.....»»

Category: topSource: bizjournalsSep 25th, 2018

Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication

Novan Inc (NASDAQ: NOVN) shares were advancing strongly Monday after the announcement of positive results for its pipeline candidate SB414. read more.....»»

Category: blogSource: benzingaAug 20th, 2018

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial f.....»»

Category: earningsSource: benzingaAug 17th, 2018

Good Bacteria Could Be Used to Fight Gut Diseases, New Research Suggests

The findings could lead to a treatment for inflammatory bowel disease......»»

Category: topSource: newsweekJul 4th, 2018

Sanofi reports results from two Phase 3 trials evaluating Dupixent

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall11 hr. 32 min. ago

BMW says trade war could hit 2019 results by up to 500 million euros

German carmaker BMW expects a hit to earnings of up to half a billion euros ($579 million) next year if tariffs between the United States and China remain in place, Chief Financial Officer Nicolas Peter told Automobilwoche magazine......»»

Category: topSource: reutersOct 12th, 2018

Ziopharm expects to respond to FDA"s request for information in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 9th, 2018

UBS expects uninspiring Skechers Q3 results, but sees concerns as priced in

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 5th, 2018

Keyera Announces Timing of 2018 Third Quarter Results Conference Call and Webcast

Keyera Announces Timing of 2018 Third Quarter Results Conference Call and Webcast Canada NewsWire CALGARY, Oct. 3, 2018 CALGARY, Oct. 3, 2018 /CNW/ - Keyera Corp. (TSX:KEY) announced today that it expects to rel.....»»

Category: earningsSource: benzingaOct 3rd, 2018

Omeros Shares Fall Over 40% On Renal Disease Trial Results

Biopharma Omeros Corporation (NASDAQ: OMER) released additional data Monday from the company’s OMS721 clinical trial in renal disease.  read more.....»»

Category: blogSource: benzingaOct 1st, 2018

Omeros stock drops 45% after kidney disease trial results

Omeros Corp. shares dropped nearly 45% in Monday afternoon trade.....»»

Category: topSource: marketwatchOct 1st, 2018

Alnylam stock drops 2.6% premarket on preliminary results for rare disease therapy

Alnylam Pharmaceuticals Inc. shares dropped 2.6% in Thursday premarket trade after the company released early results from a phase 3 trial fo.....»»

Category: topSource: marketwatchSep 27th, 2018

Aldeyra up 57% after "positive" results from Phase 2b dry eye disease trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 26th, 2018

Aldeyra announces "positive" results from Phase 2b dry eye disease trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 26th, 2018

Arena Posts Positive Phase 2 Results For Crohn"s Disease Candidate - What Investors Should Consider

Arena Posts Positive Phase 2 Results For Crohn"s Disease Candidate - What Investors Should Consider.....»»

Category: topSource: seekingalphaSep 26th, 2018

Sol-Gel expects top-line results for Epsolay in 2019

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 25th, 2018

Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S......»»

Category: topSource: marketwatchSep 18th, 2018

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

Viking Therapeutics shares more than doubled on Tuesday after the company announced results from its mid-stage non-alcoholic fatty liver disease trial......»»

Category: blogSource: 247wallstSep 18th, 2018

Why Viking Therapeutics NAFLD Study More Than Doubled Shares

Viking Therapeutics shares more than doubled on Tuesday after the company announced results from its mid-stage non-alcoholic fatty liver disease trial......»»

Category: blogSource: 247wallstSep 18th, 2018